Lung Non-Small Cell Carcinoma — Trials

Lung Non-Small Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,749
Recruiting: 926
Ph III recruiting: 138
Growth YoY: +2.3%
Industry share: 44%
Top sponsor: AstraZeneca
Termination share: 39%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,045)

clinicaltrialsPublishedShowing 751–800 of 927 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06946836	Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical Study(Neoadjuvant)	not yet recruiting	Phase 2	80	Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER	0	Apr 27, 2025	clinicaltrials
NCT05736731	A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression(EVEREST-1)	active not recruiting	Phase 1 / Phase 2